Astrana Health, Inc 8-K, filed Nov 5, 2026
Astrana Health, Inc. (ASTH)
About this 8-K
Astrana Health, Inc filed this 8-K on November 5, 2026.
Items reported
- Item 2.02: Financial results
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event
reported):
(Exact Name of Registrant as Specified in Charter)
| (State or Other Jurisdiction | (Commission | (I.R.S. Employer |
| of Incorporation) | File Number) | Identification No.) |
(Address of Principal Executive Offices) (Zip Code)
(
Registrant’s Telephone Number, Including Area Code
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered |
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 2.02 | Results of Operations and Financial Condition. |
On November 5, 2026, Astrana Health, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2026. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.
The information furnished pursuant to this Item 2.02 to this Current Report on Form 8-K, including the exhibit, is being “furnished” and, as such, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
| Item 7.01 | Regulation FD Disclosure. |
The Company has scheduled a conference call and webcast at 2:30 p.m. Pacific Time/5:30 p.m. Eastern Time on November 5, 2026 to discuss the Company’s financial results for the three and nine months ended September 30, 2026. In addition to the press release, an earnings presentation will be made available on the Company’s investor relations page at ir.astranahealth.com. A copy of the earnings presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference.
The information furnished pursuant to this Item 7.01 to this Current Report on Form 8-K, including the exhibit, is being “furnished” and, as such, shall not be deemed to be “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit No. |
Description | |
| 99.1 | Press Release of Astrana Health, Inc. Regarding its Financial Results for the Three and Nine Months Ended September 30, 2026, dated November 5, 2026. | |
| 99.2 | Supplemental Data of Astrana Health, Inc., dated November 5, 2026. | |
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ASTRANA HEALTH, INC. | ||
| Date: November 5, 2026 | By: | /s/ Brandon K. Sim |
| Name: | Brandon K. Sim | |
| Title: | Chief Executive Officer and President | |
Exhibit 99.1
Astrana Health, Inc. Reports Third Quarter 2026 Results
Company to Host Conference Call on Thursday, November 5, 2026, at 2:30 p.m. PT/5:30 p.m. ET
| · | Reports record revenue of $1,023.6 million, up 7% year-over-year, net income of $20.3 million, up 1,782% year-over-year, and record adjusted EBITDA(1) of $77.2 million, up 13% year-over-year for the three months ended September 30, 2026 |
| · | Reports net cash provided by operating activities of $117.1 million and free cash flow(2) of $105.4 million for the nine months ended September 30, 2026 |
ALHAMBRA, Calif., November 5, 2026 /PRNewswire/ -- Astrana Health, Inc. (“Astrana,” and together with its subsidiaries and affiliated entities, the “Company”) (NASDAQ: ASTH), a physician-centric, technology-enabled healthcare company empowering providers to deliver accessible, high-quality, and high-value care to all, today announced its consolidated financial results for the third quarter ended September 30, 2026.
“Our third quarter results demonstrate the growing impact of Astrana’s physician-centric, AI-native healthcare operating platform and our team’s continued focus on execution,” said Brandon Sim, President and Chief Executive Officer of Astrana Health. “We delivered record revenue, record adjusted EBITDA, and double-digit organic earnings growth while continuing to invest in the next phase of our growth. By combining proprietary technology, aligned physician partnerships, and integrated care delivery, we’re building a scalable, repeatable model to improve patient outcomes and manage the total cost of care – a value proposition that extends across payer and reimbursement models and positions us to create sustainable long-term value for patients, physician partners, and shareholders.”
Financial Highlights for Third Quarter Ended September 30, 2026:
All comparisons are to the three months ended September 30, 2025 unless otherwise stated.
| · | Total revenue of $1,023.6 million, up 7% from $956.0 million |
| · | Care Partners revenue of $968.8 million, up 8% from $897.7 million |
| · | Net income attributable to Astrana of $13.0 million, up from $0.4 million |
| · | Earnings per share (“EPS”) - diluted of $0.26, up from $0.01 |
| · | Adjusted EBITDA(1) of $77.2 million, up 13% from $68.5 million |
| · | Adjusted EPS - diluted(3) of $0.71, up 4% from $0.68 |
Financial Highlights for Nine Months Ended September 30, 2026:
All comparisons are to the nine months ended September 30, 2025 unless otherwise stated.
| · | Total revenue of $2,961.2 million, up 33% from $2,231.2 million |
| · | Care Partners revenue of $2,811.3 million, up 32% from $2,130.1 million |
| · | Net income attributable to Astrana of $47.1 million, up 186% from $16.5 million |
| · | EPS - diluted of $0.95, up 188% from $0.33 |
| · | Adjusted EBITDA(1) of $212.4 million, up 39% from $153.0 million |
| · | Adjusted EPS - diluted(3) of $2.25, up 36% from $1.66 |
| · | Net cash provided by operating activities of $117.1 million |
| · | Free cash flow(2) of $105.4 million |
| (1) | See “Reconciliation of Net Income to EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin” and “Use of Non-GAAP Financial Measures” below for additional information. |
| (2) | See reconciliation provided with the condensed consolidated statements of cash flows and “Use of Non-GAAP Financial Measures” below for additional information. |
| (3) | See “Reconciliation of Net Income to Adjusted Net Income Attributable to Astrana and Adjusted EPS - Diluted” and “Use of Non-GAAP Financial Measures” below for additional information. |
Recent Operating Highlights
| · | Closed the acquisition of an independent practice association in Georgia on October 1, 2026. |
| · | Added two Care Enablement clients, a provider group in Connecticut and a hospital in California, with both expected to onboard onto Astrana's AI-powered technology and managed services platform in early 2027. |
| · | Entered into several new Medicare Advantage payer partnerships effective January 1, 2027, with new health plan partners in markets including Southern California, Texas, and Arizona, supporting continued membership growth across the Astrana platform. |
Segment Results for three months ended September 30, 2026:
All comparisons are to the three months ended September 30, 2025 unless otherwise stated.
| Three Months Ended September 30, 2026 | ||||||||||||||||||||||||
| (in thousands) | Care Partners | Care Delivery | Care Enablement | Intersegment Elimination | Corporate Costs | Consolidated Total | ||||||||||||||||||
| Total revenues | $ | 968,757 | $ | 91,017 | $ | 92,001 | $ | (128,159 | ) | $ | — | $ | 1,023,616 | |||||||||||
| % change vs. prior year quarter | 8 | % | 5 | % | 5 | % | ||||||||||||||||||
| Cost of services | 829,490 | 69,116 | 47,915 | (46,453 | ) | — | 900,068 | |||||||||||||||||
| General and administrative expenses | 77,694 | 22,229 | 18,425 | (81,713 | ) | 31,412 | 68,047 | |||||||||||||||||
| Depreciation and amortization | 12,480 | 1,263 | 1,226 | — | 653 | 15,622 | ||||||||||||||||||
| Total expenses | 919,664 | 92,608 | 67,566 | (128,166 | ) | 32,065 | 983,737 | |||||||||||||||||
| Income (loss) from operations | $ | 49,093 | $ | (1,591 | ) | $ | 24,435 | $ | 7 | (1) | $ | (32,065 | ) | $ | 39,879 | |||||||||
| % change vs. prior year quarter | 94 | % | 56 | % | 4 | % | ||||||||||||||||||
| (1) | Income from operations for the intersegment elimination represents sublease income between segments. Sublease income is presented within other income, which is not presented in the table. |
2026 Guidance:
Based on the Company’s existing business, current view of existing market conditions, and assumptions, the Company is providing guidance for total revenue and Adjusted EBITDA for the quarter ending December 31, 2026 and narrowing guidance for total revenue, Adjusted EBITDA, and free cash flow for the year ending December 31, 2026.
| Three Months Ending December 31, 2026 | Year Ending December 31, 2026 | |||||||||||||||
| Guidance Range | Guidance Range | |||||||||||||||
| ($ in millions) | Low | High | Low | High | ||||||||||||
| Total revenue | $ | 939 | $ | 1,039 | $ | 3,900 | $ | 4,000 | ||||||||
| Adjusted EBITDA | $ | 48.5 | $ | 61.5 | $ | 261 | $ | 274 | ||||||||
| Free cash flow | $ | 107.5 | $ | 130 | ||||||||||||
See “Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA,” “Guidance Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow,” and “Use of Non-GAAP Financial Measures” below for additional information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See “Forward-Looking Statements” below for additional information.
Conference Call and Webcast Information:
Astrana will host a conference call at 2:30 p.m. PT/5:30 p.m. ET today (Thursday, November 5, 2026), during which management will discuss the results of the third quarter ended September 30, 2026. To participate in the conference call, please use the following dial-in numbers about 5 minutes prior to the scheduled conference call time:
| U.S. & Canada (Toll-Free): | +1 (877) 858-9810 |
| International (Toll): | +1 (201) 689-8517 |
The conference call can also be accessed via webcast at: https://event.choruscall.com/mediaframe/webcast.html?webcastid=PPgZy93u
An accompanying slide presentation will be available in PDF format on the “IR Calendar” page of the Company’s website (https://ir.astranahealth.com/news-events/ir-calendar) after issuance of the earnings release and will be furnished as an exhibit to Astrana’s current report on Form 8-K to be filed with the SEC, accessible at www.sec.gov.
Those who are unable to attend the live conference call may access the recording at the above webcast link, which will be made available shortly after the conclusion of the call.
Note About Consolidated Entities
The Company consolidates entities in which it has a controlling financial interest. The Company consolidates subsidiaries in which it holds, directly or indirectly, more than 50% of the voting rights, and variable interest entities (“VIEs”) in which the Company is the primary beneficiary. Non-controlling interests represent third party equity ownership interests in the Company’s consolidated entities (including certain VIEs). The amount of net income or loss attributable to non-controlling interests is disclosed in the Company’s consolidated statements of income.
About Astrana Health, Inc.
Astrana Health is a physician-centric, AI-powered healthcare company committed to delivering high-quality, patient-centered care. Built from the physician's perspective, Astrana combines its scalable care delivery infrastructure, proprietary technology platform, and aligned provider networks to enable proactive, preventive care at scale - improving patient outcomes, enhancing patient experiences, supporting provider well-being, and driving greater value across the healthcare system.
Today, Astrana supports more than 20,000 providers and approximately 1.5 million patients in value-based care arrangements through its affiliated provider networks, management services organization, and integrated care delivery clinics spanning primary, specialty, and ancillary care. Together, Astrana is building the healthcare system we all deserve - one that delivers better care, better experiences, and better outcomes for all. For more information, visit www.astranahealth.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements about the Company’s guidance for the quarter ending and the year ending December 31, 2026, ability to meet operational goals, ability to meet expectations in deployment of care coordination and management capabilities, ability to decrease cost of care while improving quality and outcomes, ability to deliver sustainable revenue and EBITDA growth as well as long-term value, ability to respond to the changing environment, statements about the Company's liquidity, and successful completion and implementation of strategic growth plans, acquisition strategy, and merger integration efforts, as well as statements regarding the material weakness in internal control over financial reporting and the Company’s ability to remediate such material weakness in a timely manner. Forward-looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of the Company’s management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in the Company’s reports to the SEC, including, without limitation the risk factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent quarterly reports on Form 10-Q. Any forward-looking statement made by the Company in this release speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.
FOR MORE INFORMATION, PLEASE CONTACT:
Investor Relations
investors@astranahealth.com
ASTRANA HEALTH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)
| September 30, 2026 | December 31, 2025 | |||||||
| (Unaudited) | ||||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 396,225 | $ | 429,474 | ||||
| Receivables, net (including amounts from related parties) | 530,889 | 374,465 | ||||||
| Income taxes receivable | — | 1,799 | ||||||
| Other receivables | 20,384 | 26,385 | ||||||
| Prepaid expenses and other current assets | 29,348 | 26,264 | ||||||
| Loans receivable | 3,128 | 4,926 | ||||||
| Total current assets | 979,974 | 863,313 | ||||||
| Non-current assets | ||||||||
| Property and equipment, net | 66,103 | 57,332 | ||||||
| Intangible assets, net | 229,533 | 270,968 | ||||||
| Goodwill | 889,390 | 865,305 | ||||||
| Income taxes receivable, net of current portion | 26,220 | 26,220 | ||||||
| Loans receivable, net of current portion | 49,374 | 48,724 | ||||||
| Investments in other entities – equity method | 27,015 | 25,637 | ||||||
| Operating lease right-of-use assets | 48,308 | 35,738 | ||||||
| Other assets | 27,515 | 25,424 | ||||||
| Total non-current assets | 1,363,458 | 1,355,348 | ||||||
| Total assets (1) | $ | 2,343,432 | $ | 2,218,661 | ||||
| Liabilities, Mezzanine Deficit, and Stockholders’ Equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable and accrued expenses | $ | 272,541 | $ | 195,912 | ||||
| Fiduciary accounts payable | 3,694 | 3,524 | ||||||
| Income taxes payable | 2,561 | — | ||||||
| Medical liabilities | 418,181 | 335,705 | ||||||
| Operating lease liabilities | 10,612 | 7,809 | ||||||
| Current portion of long-term debt | 59,831 | 47,865 | ||||||
| Other liabilities | 18,648 | 24,458 | ||||||
| Total current liabilities | 786,068 | 615,273 | ||||||
| Non-current liabilities | ||||||||
| Deferred tax liability | 7,635 | 5,491 | ||||||
| Operating lease liabilities, net of current portion | 41,392 | 31,552 | ||||||
| Long-term debt, net of current portion and deferred financing costs | 865,546 | 990,904 | ||||||
| Other long-term liabilities | 11,290 | 17,107 | ||||||
| Total non-current liabilities | 925,863 | 1,045,054 | ||||||
| Total liabilities (1) | 1,711,931 | 1,660,327 | ||||||
| Mezzanine deficit | ||||||||
| Non-controlling interest in Allied Physicians of California, a Professional Medical Corporation (“APC”) | (236,801 | ) | (234,962 | ) | ||||
| Stockholders’ equity | ||||||||
| Preferred stock, $0.001 par value per share; 5,000,000 shares authorized; and zero shares issued and outstanding as of September 30, 2026 and December 31, 2025 | — | — | ||||||
| Common stock, $0.001 par value per share; 100,000,000 shares authorized, 49,320,378 and 48,885,358 shares issued and outstanding, excluding 10,724,258 and 10,571,011 treasury shares, as of September 30, 2026 and December 31, 2025, respectively | 49 | 49 | ||||||
| Additional paid-in capital | 501,366 | 470,863 | ||||||
| Retained earnings | 355,204 | 308,379 | ||||||
| Total stockholders’ equity | 856,619 | 779,291 | ||||||
| Non-controlling interests | 11,683 | 14,005 | ||||||
| Total equity | 868,302 | 793,296 | ||||||
| Total liabilities, mezzanine deficit, and stockholders’ equity | $ | 2,343,432 | $ | 2,218,661 | ||||
| (1) | The Company’s condensed consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The condensed consolidated balance sheets include (a) total assets of $1,314.6 million and $1,276.5 million as of September 30, 2026 and December 31, 2025, respectively, that can be used only to settle obligations of the Company’s consolidated VIEs and (b) total liabilities of the consolidated VIEs of $382.6 million and $376.0 million as of September 30, 2026 and December 31, 2025, respectively, for which creditors do not have recourse to the general credit of Astrana Health, Inc., the VIE’s primary beneficiary. These VIE balances do not include $218.1 million of investment in affiliates and $8.6 million of amount due to affiliates as of September 30, 2026 and $152.2 million of investment in affiliates and $58.3 million of amount due from affiliates as of December 31, 2025, as these are eliminated upon consolidation and not presented within the condensed consolidated balance sheets. |
ASTRANA HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS)
(UNAUDITED)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue | ||||||||||||||||
| Capitation and other revenue, net | $ | 1,023,616 | $ | 956,048 | $ | 2,961,237 | $ | 2,231,243 | ||||||||
| Operating expenses | ||||||||||||||||
| Cost of services, excluding depreciation and amortization | 900,068 | 858,856 | 2,627,923 | 1,984,756 | ||||||||||||
| General and administrative expenses | 68,047 | 62,387 | 183,935 | 157,009 | ||||||||||||
| Depreciation and amortization | 15,622 | 15,595 | 46,651 | 29,348 | ||||||||||||
| Total expenses | 983,737 | 936,838 | 2,858,509 | 2,171,113 | ||||||||||||
| Income from operations | 39,879 | 19,210 | 102,728 | 60,130 | ||||||||||||
| Other expense | ||||||||||||||||
| Income from equity method investments | 860 | 1,019 | 3,128 | 532 | ||||||||||||
| Interest expense | (15,021 | ) | (17,718 | ) | (47,120 | ) | (32,408 | ) | ||||||||
| Interest income | 4,147 | 3,522 | 13,870 | 8,170 | ||||||||||||
| Unrealized gain (loss) on investments | 1,126 | (807 | ) | 6,942 | (837 | ) | ||||||||||
| Other income (loss) | 1,231 | 445 | (408 | ) | (3,487 | ) | ||||||||||
| Total other expense, net | (7,657 | ) | (13,539 | ) | (23,588 | ) | (28,030 | ) | ||||||||
| Income before provision for income taxes | 32,222 | 5,671 | 79,140 | 32,100 | ||||||||||||
| Provision for income taxes | 11,953 | 4,594 | 27,288 | 14,586 | ||||||||||||
| Net income | 20,269 | 1,077 | 51,852 | 17,514 | ||||||||||||
| Net income attributable to non-controlling interests | 7,317 | 704 | 4,725 | 1,026 | ||||||||||||
| Net income attributable to Astrana Health, Inc. | $ | 12,952 | $ | 373 | $ | 47,127 | $ | 16,488 | ||||||||
| Earnings per share – basic | $ | 0.26 | $ | 0.01 | $ | 0.96 | $ | 0.34 | ||||||||
| Earnings per share – diluted | $ | 0.26 | $ | 0.01 | $ | 0.95 | $ | 0.33 | ||||||||
| Weighted average shares of common stock outstanding – basic | 49,230,686 | 49,217,134 | 49,070,359 | 49,005,363 | ||||||||||||
| Weighted average shares of common stock outstanding – diluted | 49,915,989 | 49,473,417 | 49,586,343 | 49,311,384 | ||||||||||||
Revenue consisted of the following (in thousands):
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Capitation, net | $ | 936,662 | $ | 863,380 | $ | 2,735,374 | $ | 2,061,451 | ||||||||
| Risk pool settlements and incentives | 24,324 | 30,798 | 58,627 | 60,691 | ||||||||||||
| Management fee income | 14,105 | 15,217 | 43,001 | 20,104 | ||||||||||||
| Fee-for-service, net | 35,122 | 40,080 | 95,935 | 72,848 | ||||||||||||
| Other revenue | 13,403 | 6,573 | 28,300 | 16,149 | ||||||||||||
| Capitation and other revenue, net | $ | 1,023,616 | $ | 956,048 | $ | 2,961,237 | $ | 2,231,243 | ||||||||
ASTRANA HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)
(UNAUDITED)
| Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Cash flows from operating activities | ||||||||
| Net income | $ | 51,852 | $ | 17,514 | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | 46,651 | 29,348 | ||||||
| Amortization of debt issuance cost | 3,438 | 2,892 | ||||||
| Stock-based compensation | 37,245 | 27,219 | ||||||
| Non-cash lease expense | 6,865 | 4,348 | ||||||
| Deferred tax | 1,774 | (4,924 | ) | |||||
| Change in fair value of contingent consideration liabilities | (4,212 | ) | 4,353 | |||||
| Change in fair value of financing obligation | (3,272 | ) | — | |||||
| Other | (4,415 | ) | 609 | |||||
| Changes in operating assets and liabilities, net of business combinations | (18,849 | ) | 36,125 | |||||
| Net cash provided by operating activities | 117,077 | 117,484 | ||||||
| Cash flows from investing activities | ||||||||
| Payments for acquisitions, net of cash acquired | (6,825 | ) | (548,553 | ) | ||||
| Proceeds from sale of equity method investment | — | 15,100 | ||||||
| Purchases of property and equipment | (11,711 | ) | (7,042 | ) | ||||
| Other | 3,666 | 2,553 | ||||||
| Net cash used in investing activities | (14,870 | ) | (537,942 | ) | ||||
| Cash flows from financing activities | ||||||||
| Dividends paid | (1,127 | ) | (6,329 | ) | ||||
| Borrowings on debt | — | 1,119,300 | ||||||
| Repayments of debt | (115,899 | ) | (483,323 | ) | ||||
| Deferred financing cost | — | (19,205 | ) | |||||
| Payments of contingent liabilities | (2,864 | ) | (8,284 | ) | ||||
| Taxes paid from net share settlement of restricted stock | (5,340 | ) | (5,562 | ) | ||||
| Purchase of treasury shares | (3,893 | ) | (955 | ) | ||||
| Other | (5,937 | ) | 41 | |||||
| Net cash (used in) provided by financing activities | (135,060 | ) | 595,683 | |||||
| Net (decrease) increase in cash, cash equivalents, and restricted cash | (32,853 | ) | 175,225 | |||||
| Cash, cash equivalents, and restricted cash, beginning of period | 434,045 | 289,101 | ||||||
| Cash, cash equivalents, and restricted cash, end of period | $ | 401,192 | $ | 464,326 | ||||
| Supplemental disclosures of cash flow information | ||||||||
| Cash paid for income taxes | (1) | $ | 4,728 | |||||
| Cash paid for interest | $ | 43,647 | $ | 30,184 | ||||
| Supplemental disclosures of non-cash investing and financing activities | ||||||||
| Right-of-use assets obtained in exchange for operating lease liabilities | $ | 13,969 | $ | 7,780 | ||||
| Common stock issued for contingent consideration payment | $ | — | $ | 2,600 | ||||
| Elimination of note payable upon consolidation | $ | — | $ | 9,488 | ||||
| Dividend paid in the form of common stock | $ | — | $ | 21,935 | ||||
| (1) | Following the adoption of Accounting Standards Codification (“ASC”) 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures", cash paid for income taxes is presented net of tax refunds, for the quarterly period ended September 30, 2026, under Item 1 of the Company’s Quarterly Report on Form 10-Q. |
The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets that sum to the total amounts of cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows (in thousands):
| September 30, 2026 | December 31, 2025 | September 30, 2025 | ||||||||||
| Cash and cash equivalents | $ | 396,225 | $ | 429,474 | $ | 462,227 | ||||||
| Restricted cash (1) | 4,967 | 4,571 | 2,099 | |||||||||
| Total cash, cash equivalents, and restricted cash, end of period shown in the statement of cash flows | $ | 401,192 | $ | 434,045 | $ | 464,326 | ||||||
| (1) | Restricted cash is included in other assets on the condensed consolidated balance sheets. |
Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow
| Nine Months Ended September 30, | ||||||||
| (in thousands) | 2026 | 2025 | ||||||
| Net cash provided by operating activities | $ | 117,077 | $ | 117,484 | ||||
| Purchases of property and equipment | (11,711 | ) | (7,042 | ) | ||||
| Free cash flow | $ | 105,366 | $ | 110,442 | ||||
Reconciliation of Net Income to EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin
Set forth below are reconciliations of Net Income to EBITDA and Adjusted EBITDA, as well as the reconciliations to Adjusted EBITDA margin for the three and nine months ended September 30, 2026 and 2025. The Company defines Adjusted EBITDA margin as Adjusted EBITDA over total revenue.
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| (in thousands) | 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Net income | $ | 20,269 | $ | 1,077 | $ | 51,852 | $ | 17,514 | ||||||||
| Interest expense | 15,021 | 17,718 | 47,120 | 32,408 | ||||||||||||
| Interest income | (4,147 | ) | (3,522 | ) | (13,870 | ) | (8,170 | ) | ||||||||
| Provision for income taxes | 11,953 | 4,594 | 27,288 | 14,586 | ||||||||||||
| Depreciation and amortization | 15,622 | 15,595 | 46,651 | 29,348 | ||||||||||||
| EBITDA | 58,718 | 35,462 | 159,041 | 85,686 | ||||||||||||
| Income from equity method investments | (860 | ) | (1,019 | ) | (3,128 | ) | (532 | ) | ||||||||
| Other, net | 3,784 | (1) | 26,340 | (2) | 19,234 | (3) | 40,597 | (4) | ||||||||
| Stock-based compensation | 15,563 | 7,699 | 37,245 | 27,219 | ||||||||||||
| Adjusted EBITDA | $ | 77,205 | $ | 68,482 | $ | 212,392 | $ | 152,970 | ||||||||
| Total revenue | $ | 1,023,616 | $ | 956,048 | $ | 2,961,237 | $ | 2,231,243 | ||||||||
| Adjusted EBITDA margin | 8 | % | 7 | % | 7 | % | 7 | % | ||||||||
| (1) | Other, net, for the three months ended September 30, 2026, relates to post-acquisition integration costs and a fair value remeasurement of a previously held equity method investments that is now fully acquired, partially offset by non-cash changes to the fair value of our interest rate swap. |
| (2) | Other, net, for the three months ended September 30, 2025, relates to $13.0 million for a legal matter with a provider associated with CFC Health Plan, Inc. (“CFC HP”), transaction and other costs related to our acquisitions, including $12.7 million related to our completed acquisition of certain businesses and assets of Prospect Medical Holdings, Inc, (“Prospect”), non-cash changes in the fair value of our call option and collar agreement, and severance. |
| (3) | Other, net, for the nine months ended September 30, 2026, relates to post-acquisition integration costs, an allowance on receivables that the Company plans to recover from the payer, non-routine legal matters, severance, and a fair value remeasurement of a previously held equity method investment that is now fully acquired, partially offset by non-cash changes to the fair value of an equity purchase financing obligation and our interest rate swap. |
| (4) | Other, net, for the nine months ended September 30, 2025, relates to $13.0 million for a legal matter with a provider associated with CFC HP, transaction and other costs related to our acquisitions, including $23.6 million related to Prospect, debt issuance costs incurred in connection with our Second Amended and Restated Credit Facility, non-cash changes in the fair value of our call option and collar agreement, and severance. |
Reconciliation of Net Income to Adjusted Net Income Attributable to Astrana and Adjusted EPS - Diluted
Set forth below are reconciliations of net income to adjusted net income attributable to Astrana as well as the reconciliation to adjusted EPS - diluted for the three and nine months ended September 30, 2026 and 2025.
| Three
Months Ended September 30, |
Nine
Months Ended September 30, |
|||||||||||||||
| (in thousands, except for share and per share data) | 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Net income | $ | 20,269 | $ | 1,077 | $ | 51,852 | $ | 17,514 | ||||||||
| Income from equity method investments | (860 | ) | (1,019 | ) | (3,128 | ) | (532 | ) | ||||||||
| Other, net (1) | 3,784 | 26,340 | 19,234 | 40,597 | ||||||||||||
| Stock-based compensation | 15,563 | 7,699 | 37,245 | 27,219 | ||||||||||||
| Amortization of intangible assets attributable to acquisitions | 13,779 | 14,177 | 41,435 | 26,619 | ||||||||||||
| Tax adjustments | (5,562 | )(2) | (10,614 | )(3) | (19,052 | )(2) | (19,852 | )(3) | ||||||||
| Adjusted net income attributable to non-controlling interests | (11,747 | )(4) | (3,871 | )(5) | (16,235 | )(4) | (9,902 | )(5) | ||||||||
| Adjusted net income attributable to Astrana Health, Inc. | $ | 35,226 | $ | 33,789 | $ | 111,351 | $ | 81,663 | ||||||||
| Weighted average shares of common stock outstanding – diluted | 49,915,989 | 49,473,417 | 49,586,343 | 49,311,384 | ||||||||||||
| Adjusted earnings per share - diluted | $ | 0.71 | $ | 0.68 | $ | 2.25 | $ | 1.66 | ||||||||
| (1) | The components of other, net, as set forth in the table above, are described in the footnotes to the table under “Reconciliation of Net Income to EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin”. Please see the footnotes to such table for additional information. |
| (2) | Tax adjustments for the three and nine months ended September 30, 2026, include the tax effect for, at a 27.4% statutory blended tax rate, the adjustments made to net income of $8.8 million and $25.9 million, respectively, partially offset by 162(m) impact of $3.3 million and $6.7 million, respectively. |
| (3) | Tax adjustments for the three and nine months ended September 30, 2025, include the tax effect for, at a 27.1% statutory blended tax rate, the adjustments made to net income of $12.8 million and $25.4 million, respectively, partially offset by 162(m) impact of $1.7 million and $5.1 million, respectively. |
| (4) | Adjusted net income attributable to non-controlling interests (“NCI”) for the three and nine months ended September 30, 2026, includes net income attributable to NCI of $7.3 million and $4.7 million, respectively, as well as adjustments attributable to NCI of $4.4 million and $11.5 million, respectively. |
| (5) | Adjusted net income attributable to NCI for the three and nine months ended September 30, 2025 includes net income attributable to NCI of $0.7 million and $1.0 million, respectively, as well as adjustments attributable to NCI of $3.2 million and $8.9 million, respectively. |
Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA
| Three Months Ending December 31, 2026 | Year Ending December 31, 2026 | |||||||||||||||
| Guidance Range | Guidance Range | |||||||||||||||
| (in thousands) | Low | High | Low | High | ||||||||||||
| Net income | $ | 3,100 | $ | 9,100 | $ | 55,000 | $ | 61,000 | ||||||||
| Interest expense | 9,800 | 10,800 | 43,000 | 44,000 | ||||||||||||
| Provision for income taxes | 4,700 | 5,700 | 32,000 | 33,000 | ||||||||||||
| Depreciation and amortization | 15,300 | 17,300 | 62,000 | 64,000 | ||||||||||||
| EBITDA | 32,900 | 42,900 | 192,000 | 202,000 | ||||||||||||
| Income from equity method investments | (900 | ) | (900 | ) | (4,000 | ) | (4,000 | ) | ||||||||
| Other, net | 3,700 | 5,700 | 23,000 | 25,000 | ||||||||||||
| Stock-based compensation | 12,800 | 13,800 | 50,000 | 51,000 | ||||||||||||
| Adjusted EBITDA | $ | 48,500 | $ | 61,500 | $ | 261,000 | $ | 274,000 | ||||||||
Guidance Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow
| Year Ending December 31, 2026 | ||||||||
| Guidance Range | ||||||||
| (in thousands) | Low | High | ||||||
| Net cash provided by operating activities | $ | 127,500 | $ | 142,500 | ||||
| Cash used in purchases of property and equipment | (20,000 | ) | (12,500 | ) | ||||
| Free cash flow | $ | 107,500 | $ | 130,000 | ||||
Use of Non-GAAP Financial Measures
This press release contains the non-GAAP financial measures EBITDA, Adjusted EBITDA, Adjusted EBITDA margin, adjusted net income attributable to Astrana, and adjusted EPS – diluted, of which the most directly comparable financial measure presented in accordance with U.S. generally accepted accounting principles (“GAAP”) is net income. This press release also contains the non-GAAP financial measure free cash flow, of which the most directly comparable financial measure presented in accordance with U.S. GAAP is net cash provided by operating activities. These measures are not in accordance with, or alternatives to, GAAP, and may be calculated differently from similar non-GAAP financial measures used by other companies. We use Adjusted EBITDA, Adjusted EBITDA margin, adjusted EPS – diluted, and free cash flow as supplemental performance measures of our operations, for financial and operational decision-making, and as supplemental means of evaluating period-to-period comparisons on a consistent basis and, for free cash flow, to reflect the cash flow trends in our business. Adjusted EBITDA is calculated as earnings before interest expense, interest income, income taxes, depreciation, and amortization, excluding income or loss from equity method investments, non-recurring and non-cash transactions, and stock-based compensation. We define Adjusted EBITDA margin as Adjusted EBITDA over total revenue. Adjusted net income attributable to Astrana is calculated as net income, excluding income or loss from equity method investments, non-recurring and non-cash transactions, stock-based compensation, amortization of intangible assets attributable to acquisitions, certain tax adjustments, and amounts related to net income or loss attributable to non-controlling interests. We define adjusted EPS – diluted as adjusted net income attributable to Astrana over weighted average shares of common stock outstanding – diluted. We define free cash flow as net cash provided by operating activities minus cash used in purchases of property and equipment.
We believe the presentation of these non-GAAP financial measures provides investors with relevant and useful information, as it allows investors to evaluate the operating performance of the business activities without having to account for differences recognized because of non-core or non-recurring financial information. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of our ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators we use as a basis for evaluating operational performance, allocating resources, and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation, or as a substitute for, GAAP financial measures. Other companies may calculate EBITDA, Adjusted EBITDA, Adjusted EBITDA margin, adjusted net income attributable to the Company, adjusted EPS – diluted, and free cash flow differently, limiting the usefulness of these measures for comparative purposes. To the extent this press release contains historical or future non-GAAP financial measures, we have provided corresponding GAAP financial measures for comparative purposes. The reconciliations between certain GAAP and non-GAAP measures are provided above.
Exhibit 99.2
| November 2026 Third Quarter 2026 Earnings Supplement |
| 2 Forward Looking Statements Use of Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements include any statements about the Company's business, financial condition, operating results, plans, objectives, expectations and intentions, expansion plans, estimates of our total addressable market, our ability to successfully complete and realize the benefits of anticipated acquisitions, integration of acquired companies and any projections of earnings, the anticipated synergies and other benefits of acquired businesses and any future acquisitions, revenue, expenses, EBITDA, Adjusted EBITDA and Adjusted EBITDA margins, adjusted EPS - diluted, free cash flow or other financial items, such as the Company's projected capitation and future liquidity, our ability to successfully integrate and effectively leverage artificial intelligence capabilities in our business and operations, statements relating to our cybersecurity measures and expectations regarding our ability to contain and remediate the cybersecurity incident, expectations regarding the expected impact of changes in Medicare Advantage rates, as well as statements or expectations regarding the material weakness in internal control over financial reporting and the Company’s ability to remediate such material weakness in a timely manner and may be identified by the use of forward-looking terms such as “anticipate,” “could,” “can,” “may,” “might,” “potential,” “predict,” “should,” “estimate,” “expect,” “project,” “believe,” “plan,” “envision,” “intend,” “continue,” “target,” “seek,” “will,” “would,” and the negative of such terms, other variations on such terms or other similar or comparable words, phrases or terminology. Forward-looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of the Company’s management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in the Company’s reports to the U.S. Securities and Exchange Commission (the “SEC”), including without limitation the risk factors discussed in the Company’s last Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the SEC. Because the factors referred to above could cause actual results or outcomes to differ materially from those expressed or implied in any forward-looking statements, you should not place undue reliance on any such forward-looking statements. Any forward-looking statements speak only as of the date of this presentation and, unless legally required, the Company does not undertake any obligation to update any forward-looking statement, as a result of new information, future events or otherwise. This presentation may contain statistics and other data that in some cases has been obtained from or compiled from information made available by third-party service providers. The Company makes no representation or warranty, express or implied, with respect to the accuracy, reasonableness or completeness of such information. This presentation contains the non-GAAP financial measures EBITDA, Adjusted EBITDA, Adjusted EBITDA margin, adjusted net income attributable to Astrana, and adjusted EPS – diluted of which the most directly comparable financial measure presented in accordance with U.S. generally accepted accounting principles (“GAAP”) is net income. This presentation also contains the non-GAAP financial measure free cash flow, of which the most directly comparable financial measure presented in accordance with U.S GAAP is net cash provided by operating activities. These measures are not in accordance with, or alternatives to, GAAP, and may be calculated differently from similar non-GAAP financial measures used by other companies. The Company uses Adjusted EBITDA, Adjusted EBITDA margin, adjusted EPS – diluted, and free cash flow as supplemental performance measures of our operations, for financial and operational decision-making, and as supplemental means of evaluating period-to-period comparisons on a consistent basis, and, for free cash flow, to reflect the cash flow trends in our business. Adjusted EBITDA is calculated as earnings before interest expense, interest income, income taxes, depreciation, and amortization, excluding income or loss from equity method investments, non-recurring and non-cash transactions, stock-based compensation, and, for periods on or prior to December 31, 2023, APC excluded assets costs. Beginning in the third quarter ended September 30, 2022, the Company has revised the calculation for Adjusted EBITDA to exclude provider bonus payments and losses from recently acquired IPAs, which it believes to be more reflective of its business. The Company defines Adjusted EBITDA margin as Adjusted EBITDA over total revenue. Adjusted net income attributable to Astrana is calculated as net income, excluding income or loss from equity method investments, non-recurring and non-cash transactions, stock-based compensation, amortization of intangible assets attributable to acquisitions, certain tax adjustments, and amounts related to net income or loss attributable to non-controlling interests. The Company defines adjusted EPS - diluted as adjusted net income attributable to Astrana over weighted average shares of common stock outstanding - diluted. The Company defines free cash flow as net cash provided by operating activities minus cash used in purchases of property and equipment. The Company believes the presentation of these non-GAAP financial measures provides investors with relevant and useful information, as it allows investors to evaluate the operating performance of the business activities without having to account for differences recognized because of non-core or non-recurring financial information. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of the Company’s ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating operational performance, allocating resources, and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation, or as a substitute for, GAAP financial measures. Other companies may calculate EBITDA, Adjusted EBITDA, Adjusted EBITDA margin, adjusted net income attributable to Astrana, adjusted EPS – diluted, and free cash flow differently, limiting the usefulness of these measures for comparative purposes. To the extent this Presentation contains historical or future non-GAAP financial measures, the Company has provided corresponding GAAP financial measures for comparative purposes. The reconciliation between certain GAAP and non-GAAP measures is provided in the Appendix. The Company has not provided a quantitative reconciliation of applicable non-GAAP measures, such as the projected adjusted EBITDA to the most comparable GAAP measure, such as net income, on a forward-looking basis within this presentation because the Company is unable, without unreasonable efforts, to provide reconciling information with respect to certain line items that cannot be calculated. These items, which could materially affect the computation of forward-looking GAAP net income, are inherently uncertain and depend on various factors, some of which are outside of the Company’s control. |
| 3 Q3 2026 Financial Results Revenue $1,023.6 7%1 Adj. EPS – Diluted3 $0.71 4%1 YTD Free Cash Flow4 $105.45 5%5 Third Quarter 2026 Performance Highlights $ in millions, except for per share information 1. All comparisons are to the three months ended September 30, 2025, unless otherwise stated. 2. See “Reconciliation of Net Income to EBITDA and Adjusted EBITDA” and “Use of Non-GAAP Financial Measures” slides for more information. 3. See “Reconciliation of Net Income to Adjusted Net Income Attributable to Astrana and Adjusted EPS – Diluted” and “Use of Non-GAAP Financial Measures” slides for more information. 4. See “Reconciliation and Guidance Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow” and “Use of Non-GAAP Financial Measures” slides for more information. 5. Free cash flow is provided for the nine months ended September 30, 2026 and compared to the nine months ended September 30, 2025. Adj. EBITDA2 $77.2 13%1 NI attr. to ASTH $13.0 3,372%1 |
| 4 Actual FY 2025 Results FY 2026 Guidance Range2,3,4 Growth at Midpoint of Guidance5 Total Revenue $3,181.8 $3,900 - $4,000 24.1% Adjusted EBITDA2 $205.4 $261 - $274 30.2% Free Cash Flow3 $104.5 $107.5 - $130 13.6% Q3 2026 Financial Results1 Revenue $1,023.6 Adjusted EBITDA2 $77.2 YTD Free Cash Flow3 $105.4 1. Q3 2026 Financial Results are provided for the three months ended September 30, 2026 except for free cash flow, which is provided for the nine months ended September 30, 2026. 2. See “Reconciliation of Net Income to EBITDA and Adjusted EBITDA,” “Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA” and “Use of Non-GAAP Financial Measures” slides for more information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See “Forward-Looking Statements” on slide 2. 3. See “Reconciliation and Guidance Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow” and “Use of Non-GAAP Financial Measures” slides for more information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See “Forward-Looking Statements” on slide 2. 4. Narrowing guidance for Revenue, Adjusted EBITDA and Free Cash Flow. 5. Comparisons are to the year ended December 31, 2025, unless otherwise stated. $ in millions FY2026 Guidance |
| 5 Growth Sustainably growing membership to bring better care to more Americans Astrana now serves approximately 1.5 million patients in value-based arrangements, including approximately 1.2 million members in our Care Partners segment Closed a tuck-in acquisition of an independent physician association in Georgia on October 1, 2026 Third Quarter 2026 Highlights and Recent Updates Operating Leverage Driving operating leverage across our business through our Care Enablement suite Added two new Care Enablement clients: a primary and multispecialty care group in Connecticut and a hospital in California Year-to-date G&A expense of approximately 6.2% of revenue, improvement of approximately 80 basis points year over year Risk Progression Increasing alignment through total cost of care responsibility in value-based arrangements 82% of FY2026 capitation revenue expected to be generated under full-risk arrangements 43% of Care Partners members expected to be in full-risk arrangements by year-end Outcomes and Cost Achieving superior patient outcomes while managing cost Consolidated medical cost trend year to date tracking below our full-year assumption of approximately 5.2% Annual Wellness Visit (AWV) program has reached nearly 65% of eligible members year to date, helping identify risks earlier and close gaps in care |
| 6 Projected Full-risk Partial-risk Members by Risk Arrangement2 35% 47% 73% 76% 82% 100% 65% 53% 27% 24% 18% 2021 2022 2023 2024 2025 2026 E 43% 57% 2026 E Capitated Revenue by Risk Arrangement1 Our partial-risk membership presents an embedded opportunity for increased platform value and risk alignment. We succeed in these contracts by continuing to drive positive patient outcomes. 1. Revenue by risk arrangement represents capitation revenue only. 2. Members by risk arrangement represent Care Partners membership only. 3. 2026 E based on Full Year 2026 forecast. Prudently transitioning to full-risk contracts to better align incentives around patient outcomes and improve unit economics 2025 2026 E3 2026 E3 |
| 7 Revenue by Type1 61% 26% 9% 4% Medicare Medicaid Commercial Other Third Parties Revenue By Payer Type1 85% 15% Full-risk Partial-risk Revenue by Risk Arrangement1,2 46% 54% Full-risk Partial-risk Members by Risk Arrangement3 Our Value-Based Care Business is Diverse 1% 1. Revenue for the quarter ended September 30, 2026. 2. Revenue by risk arrangement represents capitation revenue only. 3. Members by risk arrangement represent Care Partners membership only as of September 30, 2026. 92% 2% 2% 3% Capitation, net Risk Pool Settlements & Incentives Management Fee Income Fee-for-service, net Other Income |
| 8 Revenue ($ in millions) Adj. EBITDA ($ in millions) $561 $687 $774 $1,144 $1,387 $2,035 $3,182 2019 2020 2021 2022 2023 ~32% CAGR 2024 $54.2 $102.8 $133.5 $140.0 $146.6 $170.4 $205.4 2019 2020 2021 2022 2023 2024 ~26% CAGR 2025 $3,900- $4,000 $261- $274 2026 E1 2026 E1 2025 Astrana grows profitably across all market conditions Note: For more information, see “Reconciliation of Net Income to EBITDA and Adjusted EBITDA”, “Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA”, and “Use of Non-GAAP Financial Measures“ slides for more information. 1. 2026 E based on guidance (bar is at midpoint). |
| 9 Quarter over Quarter Segment Revenue Revenue $ in millions Q3 2025 Q4 2025 Q1 2026 Q2 2026 Care Partners High-performing network of aligned providers $892.5 $909.7 Care Delivery High-quality system of employed providers $86.9 $92.1 $85.1 Care Enablement Full-stack tech, clinical, and operations platform $87.3 $78.9 $87.7 Inter-company $(115.9) $(112.9) $(117.4) Total $956.0 $950.5 $965.1 $932.8 $74.7 $85.6 $(120.6) $972.5 $897.7 Note: Numbers may not total due to rounding. Certain amounts disclosed in the prior periods have been recast to conform to the current period presentation. Specifically, segments are presented net of intrasegment eliminations. Q3 2026 $968.8 $91.0 $92.0 $(128.2) $1,023.6 |
| 10 Selected Financial Results |
| 11 Three Months Ended September 30, $ in thousands, except per share data 2026 2025 Revenue Capitation, net $ 936,662 $ 863,380 Risk pool settlements and incentives 24,324 30,798 Management fee income 14,105 15,217 Fee-for-service, net 35,122 40,080 Other revenue 13,403 6,573 Total revenue 1,023,616 956,048 Total expenses 983,737 936,838 Income from operations 39,879 19,210 Net income $ 20,269 $ 1,077 Net income attributable to non-controlling interests 7,317 704 Net income attributable to Astrana Health, Inc. $ 12,952 $ 373 Earnings per share – diluted $ 0.26 $ 0.01 EBITDA1 $ 58,718 $ 35,462 Adjusted EBITDA1 $ 77,205 $ 68,482 Adjusted EPS – Diluted2 $ 0.71 $ 0.68 Summary of Selected Financial Results 1. See “Reconciliation of Net Income to EBITDA and Adjusted EBITDA” and “Use of Non-GAAP Financial Measures” slides for more information. 2. See “Reconciliation of Net Income to Adjusted Net Income Attributable to Astrana and Adjusted EPS – Diluted” and “Use of Non-GAAP Financial Measures” slides for more information. |
| 12 $ in thousands Care Partners Care Delivery Care Enablement Intersegment Elimination Corporate Costs Consolidated Total Total revenues $ 968,757 91,017 92,001 (128,159) - 1,023,616 % change vs prior year quarter 8% 5% 5% Cost of services 829,490 69,116 47,915 (46,453) - 900,068 General and administrative expenses 77,694 22,229 18,425 (81,713) 31,412 68,047 Depreciation and amortization 12,480 1,263 1,226 - 653 15,622 Total expenses 919,664 92,608 67,566 (128,166) 32,065 983,737 Income (loss) from operations $ 49,093 (1,591) 24,435 7 1 (32,065) 39,879 % change vs prior year quarter 94% 56% 4% For the three months ended September 30, 2026 Segment Results 1. Income from operations for the intersegment elimination represents sublease income between segments. Sublease income is presented within other income which is not presented in the table. |
| 13 $ in millions 9/30/2026 12/31/2025 $ Change Cash and cash equivalents1 $396.2 $429.5 $(33.3) Working capital $193.9 $248.0 $(54.1) Total stockholders’ equity $868.3 $793.3 $75.0 Balance Sheet Highlights 1. Excluding restricted cash and marketable securities. |
| 14 1. The Company defines Adjusted EBITDA margin as Adjusted EBITDA over total revenue.; 2. Other, net, for the three months ended September 30, 2026 relates to post-acquisition integration costs and a fair value remeasurement of a previously held equity method investment that is now fully acquired, partially offset by non-cash change to the fair value of our interest rate swap.; 3. Other, net for the three months ended September 30, 2025 relates to $13.0 million for a legal matter with a provider associated with CFC Health Plan, Inc., transaction and other costs related to our acquisitions, including $12.7 million related to our completed acquisition of certain businesses and assets of Prospect Medical Holdings, Inc., non-cash changes in the fair value of our call option and collar agreement, and severance. Three Months Ended September 30, $ in thousands 2026 2025 Net Income $ 20,269 $ 1,077 Interest expense 15,021 17,718 Interest income (4,147) (3,522) Provision for income taxes 11,953 4,594 Depreciation and amortization 15,622 15,595 EBITDA 58,718 35,462 Income from equity method investments (860) (1,019) Other, net 3,7842 26,3403 Stock-based compensation 15,563 7,699 Adjusted EBITDA Adjusted EBITDA margin1 $ 77,205 8% $ 68,482 7% Reconciliation of Net Income to EBITDA & Adjusted EBITDA |
| 15 For the twelve months ended TTM Ended Year Ended $ in millions September 30, 2026 2025 2024 2023 2022 2021 2020 2019 Net Income $ 58.4 $ 24.1 $ 49.9 $ 57.8 $ 45.7 $ 46.1 $ 122.1 $ 15.8 Interest expense 64.6 50.0 33.1 16.1 7.9 5.4 9.5 4.7 Interest income (17.9) (12.2) (14.5) (14.2) (2.0) (1.6) (2.8) (2.0) Provision for income taxes 28.2 15.5 30.9 32.0 40.9 31.7 56.3 10.0 Depreciation and amortization 63.1 45.7 27.9 17.7 17.5 17.5 18.4 18.3 EBITDA1 196.5 123.1 127.3 109.5 110.1 99.1 203.5 46.8 (Income) loss from equity method investments (4.3) (1.7) (4.5) (5.1) (5.7)9 5.39 (0.3)9 2.9 Gain on sale of equity method investment - - - - - (2.2) - - Other, net 24.02 45.43 13.04 6.25 3.36 (1.7)7 (0.5)7 2.010 Stock-based compensation 48.6 38.6 34.5 22.0 16.1 6.7 3.4 0.9 APC excluded assets costs - - - 14.0 16.29 26.49 (103.3)9 1.5 Adjusted EBITDA1 $ 264.8 $ 205.4 $ 170.4 $ 146.6 $ 140.0 $ 133.5 $ 102.8 $ 54.2 Net Revenue $ 3,911.8 $ 3,181.8 $ 2,034.5 $ 1,386.7 $ 1,144.2 $ 773.9 $ 687.2 $ 560.6 Adjusted EBITDA Margin8 7% 6% 8% 11% 12% 17% 15% 10% Reconciliation of Net Income to EBITDA & Adjusted EBITDA (continued) 1. See “Use of Non-GAAP Financial Measures” slide for more information.; 2. Other, net, for TTM ended September 30, 2026, relates to post-acquisition integration costs, an allowance on receivables that the Company plans to recover from the payer, non-routine legal matters, severance, fair value remeasurement of a previously held equity method investments that is now fully acquired, and transaction and other costs related to our acquisitions including Prospect, partially offset by non-cash changes to the fair value of an equity purchase financing obligation and our interest rate swap, and employer retention tax credits related to COVID-19 relief.; 3. Other, net, for the year ended December 31, 2025, relates to $13.0 million for a legal matter with a provider associated with CFC HP, transaction and other costs related to our acquisitions including $25.9 million for Prospect, debt issuance costs incurred in connection with our Second Amended and Restated Credit Facility, and severance, partially offset by employer retention tax credits related to COVID-19 relief.; 4. Other, net for the year ended December 31, 2024 relates to transaction costs incurred for our investments and tax restructuring fees, anticipated recoveries from one time losses relating to third party payer payments associated with the CHS transaction, financial guarantee via a letter of credit that we provided in support of two local provider-led ACOs, reimbursement from a related party of the Company for taxes associated with the December 2023 Excluded Assets Spin-off, non-cash gain on debt extinguishment related to one of our promissory note payables, non-cash realized loss from sale of one of our marketable equity securities, non-cash changes in the fair value of our call option, an equity purchase financing obligation, contingent liabilities, and our collar agreement.; 5. Other, net for the year ended December 31, 2023 consists of nonrecurring transaction costs and tax restructuring fees incurred, non-cash changes in the fair value of an equity purchase financing obligation, contingent liabilities, and our collar agreement, and excise tax related to a nonrecurring buyback of the Company’s stock from APC.; 6. Other, net for the year ended December 31, 2022 consists of one-time transaction costs incurred, non-cash changes in the fair value of an equity purchase financing obligation and contingent liabilities.; 7. Other, net for the years ended December 31, 2021 and 2020 relate to COVID-19 relief payments recognized in 2021 and 2020.; 8. The Company defines Adjusted EBITDA margin as Adjusted EBITDA over total revenue.; 9. Certain APC minority interests where APC owns the asset but not the right to the dividends is reclassified from APC excluded asset costs to income from equity method investments.; 10. Other, net for the year ended December 31, 2019 is related to goodwill impairment. |
| 16 Reconciliation of Net Income to Adjusted Net Income Attributable to Astrana and Adjusted EPS - Diluted Three Months Ended September 30, $ in thousands, except for share and per share data 2026 2025 Net income $ 20,269 $ 1,077 Income from equity method investments (860) (1,019) Other, net1 3,784 26,340 Stock-based compensation 15,563 7,699 Amortization of intangible assets attributable to acquisitions 13,779 14,177 Tax adjustments (5,562)2 (10,614)3 Adjusted net income attributable to non-controlling interests (11,747)4 (3,871)5 Adjusted net income attributable to Astrana Health, Inc.6 $ 35,226 $ 33,789 Weighted average shares of common stock outstanding – diluted 49,915,989 49,473,417 Adjusted earnings per share – diluted6 $ 0.71 $ 0.68 1. The components of other, net, as set forth in the table above, are described in the footnotes to the table under “Reconciliation of Net Income to EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin”. Please see the footnotes to such table for additional information.; 2. Tax adjustments for the three months ended September 30, 2026, includes the tax effect for, at a 27.4% statutory blended tax rate, the adjustments made to net income of $8.8 million, partially offset by 162(m) impact of $3.3 million.; 3. Tax adjustments for the three months ended September 30, 2025, includes the tax effect for, at a 27.1% statutory blended tax rate, the adjustments made to net income of $12.8 million, partially offset by 162(m) impact of $1.7 million.; 4. Includes net income attributable to non-controlling interests ("NCI") of $7.3 million, as well as adjustments attributable to NCI of $4.4 million, for the three months ended September 30, 2026.; 5. Includes net income attributable to NCI of $0.7 million, as well as adjustments attributable to NCI of $3.2 million, for the three months ended September, 2025.; 6. See “Use of Non-GAAP Financial Measures” slide for more information. |
| 17 $ in thousands Actual Results Guidance1 Nine Months Ended September 30, 2026 Year Ended December 31, 2025 Nine Months Ended September 30, 2025 Year Ending December 31, 2026 Low High Net cash provided by operating activities $ 117,077 $ 114,597 $ 117,484 $ 127,500 $ 142,500 Cash used in purchases of property and equipment (11,711) (10,106) (7,042) (20,000) (12,500) Free cash flow2 $ 105,366 $ 104,491 $ 110,442 $ 107,500 $ 130,000 1. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See “Forward-Looking Statements” on slide 2. 2. See “Use of Non-GAAP Financial Measures” slide for more information. Reconciliation and Guidance Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow |
| 18 . Guidance Reconciliation of Net Income to EBITDA & Adjusted EBITDA 1. Note: See “Use of Non-GAAP Financial Measures” slide for more information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See “Forward-Looking Statements” on slide 2. 2026 Guidance Range $ in thousands Low High Net Income $ 55,000 $ 61,000 Interest expense 43,000 44,000 Provision for income taxes 32,000 33,000 Depreciation and amortization 62,000 64,000 EBITDA 1 192,000 202,000 Income from equity method investments (4,000) (4,000) Other, net 23,000 25,000 Stock-based compensation 50,000 51,000 Adjusted EBITDA1 $ 261,000 $ 274,000 |
| Investor Relations investors@astranahealth.com |
